# Systems Perspective Description Language — Continuous Pharma (SPDL-PHARMA)
**Specification Document ID:** `SPDL-PHARMA-SPEC-2026-v4.2`  
**Classification:** Open Epistemic Standard / Real-Time Zero-Heap GxP Process Analytical Substrate  
**Principal Architect:** Asse van Nix | Systems Perspective Framework & Proof-Driven Architecture Group  
**Target Environment:** Zig 0.16.0 Freestanding · Perfusion Bioreactor RTUs · Continuous Crystallizers · GAMP 5  
**Applied Standards:** ISO/IEC 14977 EBNF · GBNF Maskable · FDA 21 CFR Part 210/211 · ICH Q8/Q9/Q10/Q13 (Continuous Manufacturing) · GAMP 5 Second Edition · ASTM E2474 (PAT)  

---

## 1. Epistemic Architecture: Why Traditional GxP Batch Software Must Be Replaced

1. **The Post-Batch Testing Trap:** Pharma production relies on static recipe execution followed by days of post-batch laboratory HPLC testing. If polymorphic crystallization drifts or bio-burden surges, entire multi-million-dollar batches are discarded.
2. **GAMP 5 Validation Rigidity:** Traditional Manufacturing Execution Systems (MES) freeze software under rigid qualification scripts. They cannot adapt continuous bioreactor perfusion or anti-solvent feed rates in real time based on in-line Near-Infrared (NIR) or Raman spectroscopy.

**SPDL-PHARMA** formalizes the FDA ICH Q8 **Design Space** as a set of forward-invariant Control Barrier Functions, enabling safe real-time adaptation without re-validation.

---

## 2. Physical Invariants, DAEs & Mathematical Proof Gates

```
                           SPDL-PHARMA DESIGN SPACE
 ┌─────────────────────────────────────────────────────────────────────────────┐
 │ CONTINUOUS PERFUSION BIOREACTOR MASS BALANCE (Monod Cell Growth)            │
 │   dX_cell/dt = (mu_max * S / (K_s + S)) * X_cell - D_perfusion * X_cell     │
 ├─────────────────────────────────────────────────────────────────────────────┤
 │ POPULATION BALANCE CRYSTALLIZATION EQUATION (PBE)                           │
 │   dn(L, t)/dt + G_crystal * (dn/dL) = B_nucleation - D_breakage             │
 ├─────────────────────────────────────────────────────────────────────────────┤
 │ FDA ICH Q8 VALIDATED DESIGN SPACE MULTIDIMENSIONAL BARRIER                  │
 │   h_design(pH, DO, Temp, NIR_Purity) = Purity_actual - Purity_spec >= 0     │
 └─────────────────────────────────────────────────────────────────────────────┘
```

---

## 3. Formal ISO/IEC 14977 EBNF Grammar

```ebnf
PharmaManifest    = { Line } ;
Line              = [ Whitespace ] , ( Comment | PharmaRecord ) , Newline ;
Whitespace        = { " " | "\t" | "\r" } ;
Newline           = "\n" | "\r\n" ;
Comment           = "#" , { AnyChar - Newline } ;

PharmaRecord      = "(I) @PHARMA_INVARIANT"  , " " , InvariantFields
                  | "(A) @PHARMA_UNIT"       , " " , UnitFields
                  | "(B) @DESIGN_SPACE_BAR"  , " " , BarrierFields
                  | "(M) @PAT_ADAPTIVE_FEED" , " " , FeedFields
                  | "(T) @CQA_OBSERVER"      , " " , ObserverFields ;

InvariantFields   = "id:" , Token , " gxp_class:CLASS_A" , " ich_guideline:ICH_Q13" , " alloc_policy:ZERO_HEAP" ;
UnitFields        = "id:" , Token , " process:" , ProcessType , " working_volume_l:" , Number ;
ProcessType       = "PERFUSION_BIOREACTOR" | "CONTINUOUS_CRYSTALLIZER" | "TWIN_SCREW_GRANULATOR" | "TABLET_PRESS" ;

BarrierFields     = "id:" , Token , " target_cqa:" , Token , " min_purity_pct:" , Number , " max_dissolution_min:" , Number ;

FeedFields        = "id:" , Token , " perfusion_rate_vvd:" , Number , " nutrient_feed_ml_m:" , Number , " ph_spt:" , Number ;
ObserverFields    = "id:" , Token , " raman_api_pct:" , Number , " cell_density_e6_ml:" , Number , " do_pct:" , Number , " ph_val:" , Number ;

Token             = Letter , { Letter | Digit | "_" | "-" } ;
Number            = [ "-" ] , Digit , { Digit } , [ "." , { Digit } ] ;
Letter            = "A".."Z" | "a".."z" ;
Digit             = "0".."9" ;
AnyChar           = ? Any valid Unicode code point ? ;
```

---

## 4. GBNF Structured Sampling Grammar

```gbnf
root ::= PharmaRecord "\n"

PharmaRecord ::= "(I) @PHARMA_INVARIANT" " " InvariantFields
               | "(A) @PHARMA_UNIT" " " UnitFields
               | "(B) @DESIGN_SPACE_BAR" " " BarrierFields
               | "(M) @PAT_ADAPTIVE_FEED" " " FeedFields
               | "(T) @CQA_OBSERVER" " " ObserverFields

InvariantFields ::= "id:" [A-Za-z0-9_-]+ " gxp_class:CLASS_A ich_guideline:ICH_Q13 alloc_policy:ZERO_HEAP"
UnitFields      ::= "id:" [A-Za-z0-9_-]+ " process:" ("PERFUSION_BIOREACTOR"|"CONTINUOUS_CRYSTALLIZER"|"TWIN_SCREW_GRANULATOR"|"TABLET_PRESS") " working_volume_l:" [0-9.]+
BarrierFields   ::= "id:" [A-Za-z0-9_-]+ " target_cqa:" [A-Za-z0-9_-]+ " min_purity_pct:" [0-9.]+ " max_dissolution_min:" [0-9.]+
FeedFields      ::= "id:" [A-Za-z0-9_-]+ " perfusion_rate_vvd:" [0-9.]+ " nutrient_feed_ml_m:" [0-9.]+ " ph_spt:" [0-9.]+
ObserverFields  ::= "id:" [A-Za-z0-9_-]+ " raman_api_pct:" [0-9.]+ " cell_density_e6_ml:" [0-9.]+ " do_pct:" [0-9.]+ " ph_val:" [0-9.]+
```

---

## 5. Production SPDL-PHARMA Manifest Exemplar

```spdl
# ==============================================================================
# SPDL-PHARMA v4.2 MANIFEST: MONOCLONAL ANTIBODY CONTINUOUS PERFUSION BIOREACTOR
# Standard: ICH Q13 / FDA 21 CFR Part 211 | PAT: Real-Time In-Situ Raman
# ==============================================================================

(I) @PHARMA_INVARIANT id:INV-MAB-SUITE gxp_class:CLASS_A ich_guideline:ICH_Q13 alloc_policy:ZERO_HEAP

# --- PHYSICAL BIOREACTOR ASSET ---
(A) @PHARMA_UNIT id:BIO_PERFUSION_01 process:PERFUSION_BIOREACTOR working_volume_l:500.0

# --- FDA VALIDATED DESIGN SPACE BARRIER (CRITICAL QUALITY ATTRIBUTE) ---
(B) @DESIGN_SPACE_BAR id:BAR_MAB_PURITY target_cqa:MONOCLONAL_IGG min_purity_pct:99.2 max_dissolution_min:15.0

# --- REAL-TIME CLOSED-LOOP PAT CONTROL SLATE ---
(M) @PAT_ADAPTIVE_FEED id:FEED_STEADY_STATE perfusion_rate_vvd:1.8 nutrient_feed_ml_m:42.5 ph_spt:7.15

# --- IN-SITU PROCESS ANALYTICAL TELEMETRY ---
(T) @CQA_OBSERVER id:TEL_RAMAN_RUN raman_api_pct:99.6 cell_density_e6_ml:85.4 do_pct:48.2 ph_val:7.16
```

---

## 6. Standards Compliance Matrix

```
╔═════════════════════════════════╦══════════════════════╦═════════════════════════════════════════════════════╗
║ Dimension                       │ Verification Standard│ Enforced Implementation Evidence                    ║
╠═════════════════════════════════╬══════════════════════╬═════════════════════════════════════════════════════╣
║ Continuous Quality Release      │ FDA / ICH Q13        │ Real-time Raman CQA bound inside validated envelope.║
║ Electronic Records GxP Audit    │ 21 CFR Part 11       │ Zero-heap attestation hash over all control slates. ║
║ Design Space Enforcement        │ ICH Q8 (Pharma Dev)  │ CBF mathematically prevents state exiting boundary. ║
║ Validation Software Integrity   │ GAMP 5 Second Edition│ Formally verified single-line AST without heap bugs.║
╚═════════════════════════════════╩══════════════════════╩═════════════════════════════════════════════════════╝
```